BiomX Inc. (PHGE) Financial Ratios
9 years of historical data (2017–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
N/A
—
5yr avg: 113.81
30Y Low2.7·High46.6
ROE
↓
-316.9%
↑-94% vs avg
5yr avg: -163.1%
30Y Low-317%·High-32%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
PHGE Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
BiomX Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.0B | $3.1B | $9.6B | $144M | $56M | $416M | $1.5B | $2.2B | — | — |
| Enterprise Value | $1.0B | $3.0B | $9.6B | $144M | $44M | $374M | $1.4B | $2.1B | — | — |
| P/E Ratio → | -0.03 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | — | — | 397.17 | 46.65 | 2.65 | 8.75 | 25.60 | 25.95 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
PHGE EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — |
PHGE Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -316.9% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -316.9% | -316.9% | -130.2% | -217.0% | -82.6% | -69.0% | -42.4% | -32.3% | -46.8% | -55.8% |
| ROA | -63.8% | -63.8% | -51.9% | -74.2% | -45.8% | -48.8% | -37.0% | -29.9% | -42.9% | -46.0% |
| ROIC | -444.8% | -444.8% | -305.2% | -336.8% | -281.2% | -164.5% | -113.0% | -70.2% | -50.8% | — |
| ROCE | -66.6% | -66.6% | -159.9% | -107.6% | -52.1% | -54.5% | -40.6% | -34.3% | -46.7% | -58.8% |
PHGE Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $5M exceeds total debt of $1M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.40 | 4.90 | 0.92 | 0.42 | 0.10 | 0.01 | — | 0.00 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | -0.34 | 0.06 | -0.57 | -0.89 | -0.53 | -0.84 | -0.20 | -0.60 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -33.45 | -33.45 | -14.01 | -11.52 | -13.16 | -50.73 | -4322.57 | -346.98 | — | — |
Net cash position: cash ($5M) exceeds total debt ($1M)
PHGE Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.87x is below 1.0, meaning current liabilities exceed current assets. The current ratio has declined from 1.58x to 0.87x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.87 | 0.87 | 2.48 | 1.58 | 4.65 | 6.03 | 8.47 | 13.58 | 24.34 | 5.81 |
| Quick Ratio | 0.87 | 0.87 | 2.48 | 1.58 | 4.65 | 6.03 | 8.47 | 13.58 | 24.35 | 5.81 |
| Cash Ratio | 0.78 | 0.78 | 2.15 | 1.33 | 4.20 | 5.62 | 7.87 | 13.24 | 24.20 | 5.58 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — |
PHGE Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
BiomX Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $1.6B | $691M | $3M | $2M | $1M | $1M | $1M | $1M | $1M |
Peer Comparison
Compare PHGE with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 PHGEYou | $1B | -0.0 | — | — | — | — | -316.9% | -444.8% | — |
 LSTA | $29M | -1.7 | — | — | 14.1% | -10711.2% | -75.5% | -229.7% | — |
 ASMB | $492M | -56.2 | — | — | 99.8% | -16.8% | -5.1% | -12.2% | — |
 ACXP | $5M | -0.4 | — | — | — | — | -302.4% | — | — |
 PRAX | $10B | -24.7 | — | — | — | — | -45.8% | -65.0% | — |
 CRSP | $5B | -8.1 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
 NTLA | $2B | -3.6 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 EDIT | $297M | -1.7 | — | — | — | — | -198.1% | — | — |
 BEAM | $3B | -38.9 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 PCVX | $7B | -9.1 | — | — | — | — | -25.6% | -24.2% | — |
 ILMN | $21B | 25.5 | 19.6 | 22.6 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 9 years · Updated daily
See PHGE's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PHGE Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PHGE vs LSTA
Side-by-side business, growth, and profitability comparison vs Lisata Therapeutics, Inc..
Start ComparisonPHGE — Frequently Asked Questions
Quick answers to the most common questions about buying PHGE stock.
What is BiomX Inc.'s P/E ratio?
BiomX Inc.'s current P/E ratio is -0.0x. This places it at the 50th percentile of its historical range.
What is BiomX Inc.'s ROE?
BiomX Inc.'s return on equity (ROE) is -316.9%. The historical average is -110.3%.
Is PHGE stock overvalued?
Based on historical data, BiomX Inc. is trading at a P/E of -0.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.